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 The billion dollar pharmaceutical research and development pipeline suffers 
greatly from high attrition rates of novel therapeutic compounds within pre-clinical and 
clinical trials. Poor bioavailability in many new drugs, originating in the various 
methodologies of high throughput screening, may explain part of these growing failure 
rates. One interpretation of this phenomenon relies on bioavailability’s correlation with 
aqueous solubility; much modern processing allows chemicals to fully develop without 
touching water, yielding upwards of 90% of new chemical entities practically insoluble 
in aqueous media. Thus, one approach to alleviating bioavailability and potentially 
clinical attrition rates necessitates augmented aqueous solubility. The amorphous 
nanoparticle presents the largest boost in aqueous solubility of a chemical through 
processing alone.  
 In this contribution, we propose electrospray as a novel, competitive candidate to 
produce pharmaceutical amorphous nanoparticles with the intent of augmenting 
solubility. Electrospray represents an idyllic nominee for three reasons: repeatability, 
flexibility, and scalability. Electrospray offers low batch to batch variation with less than 
30% relative standard deviation between various droplets. This triumphs over the several 
orders of magnitude in variation in pneumatic sprays. Electrospray’s flexibility draws 
from its ability to attain diameters over several orders of magnitude, ranging from 
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hundreds of microns to several nanometers; in this contribution droplets are produced 
between 500 𝑛𝑚 and 1 𝜇𝑚. Finally, electrospray displays scalability to any industrial 
requirement; though a single nozzle operates at mere microliters per hour, a single 
multiplexed array of emitters may increase this throughput by several orders of 
magnitude. 
 This exploration, utilizing Indomethacin as a model low solubility chemical, 
verifies electrospray as a compatible processing tool for the pharmaceutical industry. 
Scanning electron microscopy coupled with the image analysis software ImageJ gleans 
the size and shape of emitted (and dried) particles. Amorphicity verification of particles 
employs grazing angle x-ray diffraction. Finally, ultraviolet and visual spectrum 
spectroscopy evaluates the solubility advantage of particles. 
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CHAPTER 1: BIOAVAILABILITY AND SOLUBILITY 
 
1.1 Pharmaceutical Research and Development Overview 
The biopharmaceutical industry grosses over a trillion dollars annually (IMS 2012) 
and constantly expands via the discovery of new chemical entities. In order for these new 
drugs to become profitable and help people, they must pass FDA clinical trials as well as 
a preclinical battery. This process suffers from a substantial attrition rate demonstrated 
in Figure 1. 
 
Figure 1: Attrition in the Pharmaceutical R&D Pipeline 
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Unfortunately for pharmaceutical developers, this attrition rate is only worsening 
with time. The issue is complex but owes some responsibility to screening processes and 
their effect on bioavailability. 
1.1.1 Screening 
 Pharmaceutical research and development finds potential drug candidates 
through target based screening, phenotypic screening, modification of natural substances 
and biologic based approaches (Swinney et al, 2011). Most high potential chemicals come 
from the target based and phenotypic screening; these are high throughput, 
combinatorial processes. Target based screening allows for rational design of small 
molecule. This molecule design process finds chemical groups which react well with a 
certain target. Utilizing high throughput chemical libraries, these chemical groups find a 
suitable backbone yielding a final product. Phenotypic screening pushes high throughput 
screening to its limit; the process combinatorially tests vast libraries of chemicals until 
something meets the desired criterion. Since water tends to not facilitate chemical 
reactions as rigorously as these screening processes would prefer, dimethyl sulfoxide 
(DMSO) or polyethylene glycol (PEG) are almost always used as the solvent 
environment. (Babu, 2011) These non-aqueous environments of development can lead to 




1.1.2  Biopharmaceutical Classification System 
 The Biopharmaceutical Classification System (BCS), pioneered by Amidon et al., 
specifically outlines how drugs can be classified and the system has been adopted widely 
throughout the industry. This system draws two qualifying lines of properties: solubility 
and permeability. Solubility, in this context, refers to the ratio between the saturation 
limit of a drug in water and the maximally effective dose. A non-dimensional constant is 
introduced to represent that number. Permeability is a measure of how well a chemical 
will pass through the body’s biological boundaries and is measured by a partitioning 
constant. In the current state of biopharmaceutical research, good permeability comes 
readily from the screening process but solubility remains an elusive property for the 
pharmaceutical industry. With two independent quantities defining these chemicals, four 
classes naturally form from the different combinations of high and low solubility and 
permeability. Figure 2 demonstrates graphically the BCS and approximate distribution 




Figure 2: The BCS and Relative Distribution of Market and Research Drugs 
1.1.3 Pharmacodynamics and Pharmacokinetics 
Pharmacodynamics is the effect a drug has on the body. Target based screening 
focuses solely on the pharmacodynamics of a chemical. Tremendous resources are 
allocated in treating a symptom or specific efficacy criterion. Pharmacodynamics drives 
the entire innovation process within the pharmaceutical pipeline. Other critical 
properties also contribute to the success of a drug in the body. 
Pharmacokinetics describes the absorption of the drug into the body, the 
distribution of the substance through the body, the metabolization of the chemical into 
waste product, and the excretion of those waste products safely out of the body. Those 
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four items constitute the ADME summary of pharmacokinetics. More generally, 
pharmacokinetics describes the body’s effect on the drug i.e. how the body’s systems 
handle it. Pharmacokinetic properties are determined by a host of factors but among the 
most important is the bioavailability of a compound, or the fraction of an administered 
dose that reaches the bloodstream. Bioavailability constitutes the first half of the 
pharmacokinetic story (absorption and distribution) and determines if and how a drug 
will act. Further, bioavailability strongly correlates with the qualities outlined in the BCS, 
solubility and permeability. Thus, while phenotypic and target based screening tackle the 
problem of pharmacodynamics, it is the solubility and permeability of a compound 
which largely indicate the pharmacokinetics. 
1.2 Solubility  
Because of the screening processes, many NCE products are designed without 
much thought into the pharmacokinetics and BCS properties. In fact, the unintended 
consequences of the high throughput screening are a shift towards high molecular 
weights and increasing lipophilicity. It has been reported that 40% of all marketed drugs 
are poorly water soluble. Further, between 70 and 90% of new chemical entities in the 
research pipeline suffer from low solubility (Thayer, 2010). It is widely accepted that 
tackling solubility issues in these drugs represents one of the largest challenges in drug 
development. Finally it is not enough to improve the saturation concentration but also 
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boost the dissolution rate since these chemicals have a limited amount of residence time 
in the digestive system. 
This contribution focuses heavily on the improvement of solubility via processing 
of drugs (without chemical manipulation). To accomplish this effectively, parameters of 
solubility must be defined. First, the saturation limit of a chemical describes the highest 
concentration a solute will dissolve to inside a solution. This saturation limit is dependent 
on several things discussed in greater detail below. When boosting the solubility, 
supersaturation becomes a critical parameter. Supersaturation describes the ratio of the 




CHAPTER 2: THERMODYNAMIC AND DYNAMIC CONSIDERATIONS  
 
After considering thermodynamics and molecular dynamics of the problem, an 
amorphous nanoparticle emerges as the prime candidate to augment solubility.  
2.1 Thermodynamic Considerations 
 Dissolution is largely a thermodynamic phenomenon. A lower energy state in 
solution must coax each individual molecule from its solid bulk into a dissolved state. 
Successful dislodging of molecules relies on the outward force, here the dissolution 
pressure, to overwhelm the attractive forces of the solid state. These include all manner 
of intermolecular forces including dipole forces or van der Waals forces. To improve both 
saturation solubility and dissolution rate, these forces must reach minimum. These may 
be analyzed in bulk by use of enthalpy and Gibbs ‘Free Energy.’ A solid with higher free 
energy and enthalpy is expected to have more favorable thermodynamic properties, 
including solubility (Hancock, Zografi 1997).  
2.1.1 Solid State 
 The energy associated with a solid depends greatly on its solid state. Many, if not 
most, solids may exist as several different polymorphs. Many of these polymorph 
arrangements involve merely changing the crystal lattice arrangement. Long range order, 
in general, indicates a stable state with energy sunk into the crystalline order. The 
amorphous solid state describes a solid state wherein molecules exhibit no long range 
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order. This solid state has no crystal lattice; the atoms are merely jumbled together. This 
solid state has the highest free energy of all solid states. Consequently it also displays the 
most extreme thermodynamic properties. Figure 3 shows the Free Energy advantage of 
the amorphous solid state (there called a glass) over its crystalline counterparts. 
 
Figure 3: Characteristic Free Energy-Temperature Diagram for an Arbitrary Chemical  
s  
2.1.2 Amorphous Characteristics 
 The traditional formation of amorphous solids involves cooling. When cooled 
below its freezing point, a material tends to crystallize into a solid. By preventing that 
mechanism, the material enters a ‘supercooled’ liquid phase. In this phase, molecular 
mobility begins to diminish along, accompanying a rising viscosity. At another critical 
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temperature, called the glass transition temperature, this viscosity spikes and the material 
becomes practically frozen in a disordered state. Figure 4 shows the change in the 
arrangement between an ordered crystal lattice and the jumbled, disordered amorphous 
state. 
 
Figure 4: Crystal Lattice vs. Amorphous Solid Example 
 In many cases, time scales of solidification interrupt the crystallization process. For 
example, the rapid cooling of a melt often outpaces the crystallization process. Another 
example in which we take great interest involves the rapid precipitation from solution 
(Hancock, Zografi 1997). 
2.1.3 Amorphous Solubility Advantage 
 Hancock and Parks have done extensive work in evaluating a solubility advantage 
of amorphous solids. This study chose Indomethacin for detailed examination but also 
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examined several other drugs for somewhat less detailed analysis. The amorphous state 
of the studied drugs were obtained via quench cooling of molten material. They were 
then compared with the crystalline forms of that drug. 
2.1.3.1 Theoretical 
 In the above referenced work, they predict the solubility advantage with a quite 
simplified free energy model. Parks and co-workers (Parks 1928, 1934) developed this 
model for the solubility advantage of amorphous chemicals. 
Δ𝐺 = −𝑅𝑇𝑙𝑛 (
𝜎𝑎
𝜎𝑐
)      (1) 
 Clearly, this model predicts that higher free energy yields a much higher solubility 
ratio. This simple model approaches the amorphous solid state as a pseudo-equilibrium 
solid state at all temperatures below the glass transition temperature. Since the 
amorphous state has the highest possible free energy, it should also be most soluble. 
Almost astonishingly, this model predicted the solubility of the amorphous chemicals to 
fit anywhere from 12 to 1652 times the solubility of the crystalline form. 
2.1.3.2 Experimental 
 The experimental data in this study aligns well qualitatively but departs 
quantitatively from the free energy model. In the case of Indomethacin, the solubility 
ratio was predicted between 25 and 104 but the measured solubility ratio was 4.5 at room 




Figure 5: Dissolution Profile of Amorphous and Crystalline IMC at 25 Degrees Celsius 
 There are some important things to note about the dissolution profile in Figure 5. 
First, the concentration of the crystalline substance appears to quickly rise to its saturation 
limit as predicted. In the amorphous case, a sharp peak occurs to the maximum solubility 
limit. The saturation then meanders down to a ‘steady state’ concentration (much less 
than the peak). The presented solubility ratio refers to the drastic peak rather than the 




Figure 6: Dissolution Profile of Amorphous and Crystalline IMC at 5 Degrees Celsius 
 For comparison, the dissolution profile at 5℃ is presented in Figure 6. In contrast 
to Figure 5, at this cooler temperature the saturation peak seems far less drastic and the 
steady state condition maintains a larger solubility gap. At this cooler temperature, the 
predicted solubility ratio was higher than at room temperature, stated as 38-301. The 
measured solubility ratio was 4.4. 
2.1.3.3 Discrepancy 
 The tremendous quantitative discrepancy between theoretical and experimental 
data attributes to the incompleteness of the model. An explanation presented by Hancock 
and Parks derives from the strong recrystallization force from a supersaturated medium. 
Regardless of this precipitative trend, the qualitative solubility advantage is undeniable. 
A quadrupling of solubility significantly impacts the possibility of moving a drug from a 




The dynamics of dissolution and solubility stand on the pillars of surface area and 
particle curvature. Both of these properties depend strongly on particle size and shape. 
2.2.1 Surface Area 
When discussing surface area, a critical step involves fixing the amount of mass. 
In a pharmaceutical sense this manifests as the dosage level. It therefore becomes useful 







.      (2) 
Naturally, when density is held fixed this relationship becomes the ratio of surface 












= 3𝑑−1.    (3) 
Equation 3 yields the result that given a certain amount of mass to break into 
spherical particles, surface area increases monotonically (and asymptotically) as diameter 
shrinks.  
2.2.2 Dissolution Rate 
Dissolution rate experienced great growth in understanding in the early part of 
the 20th century. First, Noyes and Whitney in 1897 proposed that the dissolution rate was 
proportional to the difference between the concentration of the solution and the 
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saturation concentration. Brunner and Tolloczko made another leap in 1900 by proposing 
that dissolution rate also scaled directly with surface area. That the dissolution rate scales 
with exposed area provides a convenient method to improve the dissolution rate. Finally 
Nernst and Brunner included the conclusions of Fick’s second law into the dissolution 
rate in 1904, finding that dissolution rate was inversely proportional to the diffusion layer 
thickness. All told, the statement of a fully evolved Noyes-Whitney equation is presented 






      (4) 
2.2.3 Curvature Effects 
For most cases, saturation solubility is constant for a given material. This 
relationship maintains validity for all sizes until a critical particle size of 1-2 𝜇𝑚 below 
which saturation solubility becomes functionally dependent on size. It becomes apparent 
at these small sizes that as particle size decreases, saturation solubility increases 
(Junghanns and Muller 2008). The reasoning behind this phenomenon relies on the 
curvature of submerged particles. 
When considering the effect of curvature on solubility, important analogies must 
form. According to Junghanns and Muller (2008), “The situation of a transfer of molecules 
from a liquid phase (droplet) to a gas phase is in principal identical to the transfer of 
molecules from a solid phase (nanocrystal) to a liquid phase (dispersion medium). The 
vapor pressure is equivalent to the dissolution pressure.” With this analogy in place, 
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properties of vaporization apply analogously to dissolution. Importantly, increasing 
dissolution pressure also increases equilibrium solubility. 
An important relation in the world of vaporizing droplets (and in dissolving 
particles) comes from the Kelvin equation, stated below. This equation demonstrates a 
tremendous rate of increase in vapor pressure with radius tending to zero but relatively 
small effects for relatively large radii. 
𝑝 = 𝑝0 exp (
2𝛾𝑉𝑚
𝑟𝑅𝑇
)     (5) 
The Kelvin equation, coupled with the analogy between dissolution and 




CHAPTER 3: ATOMIZATION AND EVAPORATION 
 
3.1 Electrospray 
Electrospray describes one method of atomizing a liquid into a field of droplets. 
This method attracts interest for three primary benefits. First, electrospray produces 
primary droplets which are monodisperse, or have small variation in size within the 
droplet population. Second, tuning experimental parameters allows for enormous 
variation in mean droplet diameters, ranging from hundreds of microns down to mere 
nanometers. Finally, these desirable droplet characteristics emerge without dependence 




Figure 7: Left: Stable Taylor Cone and ES Shroud; Right: Schematic of Jet Breakup 
The mechanism of electrospray uniquely relies on electro-hydrodynamic forces and their 
interplay with surface tension. A brief overview of uncharged spray like phenomena 
(hereon referred to as ballistic emission) aids the natural implementation of electrostatic 
effects. 
3.1.1 Ballistic Jet 
Consider a hollow rigid column with an end exposed to the environment (a 
nozzle) and liquid flowing toward the exposed end. One expects this liquid, once ejected 
from the nozzle, to form a column of liquid on the basis of inertia (note: inertia generally 
scales with density, 𝜌, and the square of velocity, v. This expectation decomposes as 
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dominates the behavior of this liquid as inertial values decrease. The relative magnitudes 
of inertial forces are compared with surface tension forces in the dimensionless Weber 
number (equation 6) and frequently appears in the analysis of liquid jets, jet breakup, and 




      (6) 
The competition between surface tension and inertia in ballistic emission results 
in two distinct modes of operation: dripping and jetting. While technical descriptions of 
these modes exist, a more direct understanding evolves from example. Any household 
faucet operates in the jetting mode during full use but experiences the dripping mode 
during much smaller flow rates. 
3.1.2 Electrospray Jet 
Electrospray throws another hat in the ring of this match between inertia and 
surface tension. Consider further a high voltage applied between the previously 
described nozzle (with the added condition that the nozzle conduct electricity) and a 
grounded plane some distance away. This high voltage creates an electric field between 
the nozzle and the ground. Charge carriers within the fluid feel a force from exposure to 
this field, generally directed toward the ground. This force competes directly with surface 




The above description heavily simplifies the process and serves only to yield an 
intuitive understanding of the phenomenon. In fact, electrospray relies on a complex 
array of factors including the precise geometry of the electric field, supplied fluid flow 
rate, nozzle diameter, and especially solution properties. Among the solution properties, 
some of the most critical to the process are surface tension 𝛾, viscosity 𝜇, electrical 
conductivity k, and the dielectric constant 𝜀 (Almeria 2010). The rather intensive influence 
on solution properties implies the necessity of appropriate planning in the production of 
ink. Experimental parameters to be adjusted then become flow rate and voltage.   
3.1.4 Stability 
This competition results mostly in chaos; the exposed liquid rapidly oscillates 
between states of surface tension and electrostatic domination.  There exists a small 
region of stability within the control parameters where this chaos subsides and a stable 
solution emerges. This solution involves a linear drawdown in diameter of the exposed 
jet until the diameter reaches some small fraction of the original diameter of the nozzle. 
Once the diameter shrinks to the characteristic value, an incredibly small jet emerges. The 
name ‘Taylor Cone’ refers to this stable island and represents the preferred mode of 
operation for electrospray.  
As previously mentioned, the Taylor Cone operates at a small island of 
parameters. More practically, for a given solution, only a certain range of flow rates may 
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sustain a stable cone-jet mode of emission and that Taylor Cone appears between two 
voltage values. This carves a domain space out of the Flow Rate – Voltage Plane within 
which we expect stable operation. This domain space changes drastically between 
different solutions (on the basis of solution characteristics). 
3.1.5 Droplets 
The field of droplets in electrospray also exhibit interesting phenomena. The 
droplets contain a charge due to the electric potential. This charge leads to interesting 
divergence from the ballistic case. 
Again for comparison, consider the ballistic case. If operating in a jetting mode, 
then the column of liquid will propagate through the environment. The instability of this 
jet causes it to decompose into a series of droplets (Rayleigh). These droplets then proceed 
along their path subject only to outside forces such as gravity. Without external methods 
of distributing these droplets over an area, they simply stack at their ballistic target. 
The case of charged droplets diverges significantly from the ballistic case. The 
small jet erupting from the tip of the Taylor Cone still decomposes into droplets as 
expected. These droplets, however, are strictly bimodal and contain charge. The jet breaks 
into two types of droplets: larger primary droplets and smaller satellite droplets. The 
intrinsic charge in each droplet repels each other droplet by traditional Coulombic 
repulsion (since they are all of like-charge). The smaller droplets feel a greater 
acceleration (owing to the smaller mass) and repel to an outer shroud. The primary 
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droplets remain in the core of the droplet cloud. These primary droplets exhibit the best 
monodispersity (~10% RSD). Even these primary droplets remain at the relative core of 
the cloud of droplets, the electrostatic repulsion self-disperses the droplets over an area 
here called the footprint of the spray. 
The size of these droplets, often the defining desirable result of electrospray, 
generates healthy interest. Though many models and scaling laws exist, the most 
common was proposed by de la Mora and Loscertales (1994). Droplet diameter scaling 
with the cube root of flow rate is the most significant takeaway, but the formula is shown 
below. 






     (7) 
where 𝐺(𝜀) is a function of unity order. 
3.1.6 Multiplexing 
 The impetus for multiplexing electrosprays is simple. A single cone jet operates at 
flow rates of liters per year while industrial standards command liters per minute. The 
only way to attain such a massive scale up while maintaining the quality of electrospray 
desired lies in multiplicity. If the number of nozzles may increase without bound, then 
any throughput requirement may be met. Since cost of manufacturing nozzles scales with 
area manufactured, cost per nozzle naturally decreases with improved packing density 
(Deng, 2009). Increasing packing density can be attained through reduction of nozzle size. 
Smaller nozzle sizes minimize the amount of solvent which evaporates from the 
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meniscus, thus minimizing the cost of recovering or losing that solvent. Further, 
augmented packing density improves the homogeneity of the electrospray cloud thus 
improving performance per nozzle or per apparatus. Deng et al. (2006, 2009) has 
demonstrated some of the best packing densities for area coverage as shown in Figure 8. 
 
Figure 8: Multiplexing Device with Hexagonally Distributed Nozzles (Deng, 2009) 
Another multiplexing method is the linear array where nozzles are not arranged 
throughout an area but rather in a line. Linear packing yields cheap and compact nozzle 
arrays without suffering from losses in homogeneity (Lojewski et al, 2013). This spatial 
compactness is well suited for many manufacturing processes, especially the so called 
roll-to-roll method where the product is in motion. This motion can effectively eliminate 
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the requirement for two dimensional depositors in order to produce two dimensional 
depositions. 
3.2 Evaporation 
When producing particles via spray drying, evaporation plays a central role. With 
respect to the production of amorphous nanoparticles and the maximization of surface 
area, the critical effects of evaporation are droplet lifetime and particle morphology. 
3.2.1 Droplet Lifetime 
Though only a simplified model of evaporation, the 𝑑2 model of droplet 
evaporation suitably covers most cases of small molecule solutions. The 𝑑2 model states  
𝑑2(𝑡) = 𝑑0
2 − 𝜅𝑡.     (8) 
Thus, in a droplet, the surface area decreases linearly with time. An important 





.      (9) 
Hence, smaller droplets have much shorter lifetimes than large droplets. 
3.2.2 Frustration of Crystallization 
 To produce an amorphous solid by precipitation out of solution, nucleation must 
vastly outpace crystal growth (Mullin 2001). Further, the crystal growth rate is bounded 
linearly by the supersaturation of the solvent by the Burton-Cabrera-Frank 
supersaturation growth relationship. Further, the classical model of nucleation proposed 
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by Volmer in 1925 yields precedent for a highly nonlinear (and accelerative) relationship 
between nucleation and supersaturation. Thus as supersaturation increases, nucleation 
becomes the dominant phenomenon. The degree of amorphicity relies heavily on this 
supersaturation in solution. The specific relationship between the two and any 
optimization which might occur is beyond this contribution. We simply conclude that as 
the droplet diameter decreases (and droplet lifetime) that the metastable supersaturation 
will increase thus increasing the nucleation rate relative to crystal growth. Since the 
evaporation rate of solvent also effects the droplet lifetime, increasing the volatility of 




CHAPTER 4: EXPERIMENTAL APPROACH AND VALIDATION 
 
In this contribution, we propose electrospray as a production method for 
amorphous nanoparticles of poorly soluble therapeutic agents. Electrospray 
demonstrates necessary qualities for the process including a capacity to produce very 
small droplets and flexibility to many conducting solvents. Two other properties elevate 
electrospray’s alignment within the pharmaceutical field: scalability and monodispersity. 
The expansion of multiplexing by Deng and others have propelled electrospray into low 
cost scale up to any industrial need. Further, the uncommon property of monodispersity 
dramatically increases reproducibility, minimizing batch to batch variation. 
A model drug is chosen to represent many Class II drugs. A solvent which may 
dissolve the model drug and fit well with electrospray forms the solution headed to 
further analysis. Four properties need evaluation: size, shape, crystallinity, and solubility 
profile. Scanning Electron Microscopy evaluates the morphology of the particles. X-Ray 
diffraction reveals sample crystallinity. Finally, UV-Vis Spectroscopy is utilized to form 
a dissolution profile (concentration over time) to evaluate a real solubility advantage. 
Each of these three methods of analysis require different experimental parameters 
discussed in detail below. 
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4.1 Model Drug 
 Indomethacin (IMC), a hydrophobic and poorly water soluble drug, represents an 
ideal chemical for study because literature has already explored this substance with great 
zeal (Babu and Nangia 2011; Andronis et al 1996; BASF 2011; Hancock Zografi 1996; Jain 
2000; Hancock and Parks, 2000; Hernandez et al, 2008; Yamamoto 2012). The chemical 
structure of IMC is shown in Figure 9. 
 
Figure 9:  Molecular Structure of Indomethacin 
 Of course, properties of the IMC will be critical to its analysis. The relevant 
properties are presented in Table 1. The indomethacin in this study was acquired from 








Table 1: Properties of Indomethacin 
 
4.2 Solvent choice and Solution Properties 
 Electing a solvent for processing presents a deal of complexity, especially when 
involving electrospray. First and foremost, this solvent will need to dissolve IMC. It must 
have favorable characteristics for electrospray. If those conditions are met, then things 
such as cost and toxicity may influence the decision.  
 Indomethacin, though practically insoluble in water, shows reasonable solubility 
in ethanol, the ethers, acetone, castor oil, and chlorinated solvents. Castor oil and the 
chlorinated solvents tend to perform poorly as electrospray feed. Acetone and ethanol 
are more polar than many of the ethers. Between acetone and ethanol, neither is 
superior for electrospray. Acetone shows further promise in the production of 
amorphous particles due to the high volatility of acetone. This decreases the droplet 
Property Value Unit
Molecular weight 358 g∙mol
-1
Aqueous Solubility 0.937 mg∙L
-1
Melting Point 438 K
Glass Transition 320 K
ρ (crystalline) 1.38 kg∙m
-3
ρ (amorphous) 1.32 kg∙m
-3




lifetime. Because of this, acetone is used for the solvent in the electrospray feed. The 
relevant properties of acetone are presented in Table 2. 
Table 2: Properties of Acetone 
 
4.3 Experimental Procedure 
 First a solution of indomethacin and acetone was made. In these experiments a 
solution of 1.5%wt indomethacin was used. The solution is then loaded into a 9.5 mm 
diameter syringe  and loaded into a Model NE-300 New Era Pump Systems Inc. syringe 
pump operating at 12 V and .75A. The flow rate needs to minimize for the smallest 
droplet possible. While a stable cone could not be held indefinitely at 100 microliters per 
hour, 150 microliters per hour showed indefinite stability. The nozzle used was a 250 𝜇𝑚 
ball tip of a ball point pen. This pen tip serves the same function as a hollow nozzle 
though exhibits a larger stability island due to the viscous impedance created by the ball. 
Similarly, a flat tipped hollow nozzle could have been used. The working distance 
between the nozzle and substrate was chosen to be excessively large such that the 
Property Value Unit
Molecular Weight 58 g∙mol
-1
Boiling Point 177.65 K
Vapor Pressure 24 kPa
Density 791 kg∙m
-3




droplets were guaranteed to fully dry by the impact time. The droplet lifetime of a 5𝜇𝑚 
droplet of acetone (evaporation constant of 2 ∗ 10−8
𝑚2
𝑠





Overestimating the steady droplet speed as 10 
𝑚
𝑠
, the distance a droplet should require 
for full evaporation is roughly 1 cm. For these trials, a working distance of no less than 4 
cm were used. The stability voltage varied for each trial, but a voltage was consistently 
chosen between 1 and 10 kV. This value mostly comes as a result of the other parameters 
and is set merely to achieve stability. Each experiment presents the full array of 
experimental parameters which accompany that run. 
4.4 Morphological Studies 
Although the applicable product to the pharmaceutical industry is powder, all 
samples in this study were deposited onto some substrate. For analysis under scanning 
electron microscopy, samples were deposited on copper coated silicon wafers. Because 
IMC may not conduct electricity, all samples underwent a sputter coat of gold and 
platinum for 90 seconds. First, several single layer deposition of particles allowed for 
sizing analysis of individual particles. Then, an increased exposure time sample 
elucidated an interesting development. 
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4.4.1 Crystalline Indomethacin 
When seeing the micrographs of deposited Indomethacin, a crystalline reference 
state is useful. Figure 10 shows the morphology of the crystalline indomethacin 
purchased from Sigma Aldrich. 
 
Figure 10: Micrograph of Crystalline Indomethacin 
31 
 
4.4.2 Monolayer Deposition 
4.4.2.1 Flow Rate Dependence 
 Recall that the droplet size of electrospray is proportional to the cube root of flow 
rate. Because we desire small droplets, minimal flow rate is necessary. To verify the cube 
root dependence, IMC was spray deposited twice: once at a flow rate of 150 microliters 
per hour and once at 8 times that flow rate.  The precise experimental parameters given 
in Table 3.  














Flow Rate 0.15 mL/h Flow Rate 1.2 mL/h



















Voltage 6.2 kV Voltage 6.57 kV
Date 2/19/2014 Date 2/19/2014
Experimental Parameters Experimental Parameters
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The resulting morphologies are given in Figures 11 and 12. By inspection, it is clear 
that the scaling law holds generally. In this deposition, the particles are morphologically 
odd in the case of smaller flow rates but more spherical in the larger flow rate case. This 
modulation of morphology is not unimportant as all deviation from a sphere increases 
specific surface area.  
 




Figure 12: Micrograph of Higher Flow Rate Deposition 
4.4.2.2 Sizing Study 
In this monolayer deposition study, the experimental apparatus deposited a 
solution of IMC for a short time to gather a single layer of particles. The experimental 
parameters are collected in Table 4. A flow rate of 150 microliters per hour is the smallest 









Table 4: Experimental Parameters of the Sizing Study 
 
This sample was examined under a Phenom SEM and several pictures were taken 
at 7750x magnification. One such image is shown in Figure 13. The particles formed 
























Figure 13: Micrograph  of the Deposition Used for Sizing 
These images were then analyzed in ImageJ image analysis software (NIH) for the 
size distribution of the particles. The results from this size distribution are presented in 
Table 5. Even with a reasonably high sample population, the relative standard deviation 








Table 5 Resutls of the Sizing Study 
 
4.4.3 Multilayer Deposition 
In later trials, a larger volume than a single layer becomes necessary for analysis. 
To gauge the type of matrix formed by layers of these particles, low weight solution of 
IMC in acetone was spray deposited for an extended time span. The experimental 






















Table 6: Experimental Parameters of a multilayer deposition 
 
Figure 14 shows the resulting particle matrix. Interestingly, the powder does not 
appear as a stack of spheres as one would expect of a powder, but rather an 
interconnected matrix with some degree of continuity. The matrix still tends to bulge as 
if retaining memory of its constituent particles but does not appear to be dispersed. That 
being said, the branches apparent in Figure 14 are of characteristic length consistent with 
the sizing study; the thicker bulges average in the 700 nanometer range with a tolerance 
of roughly 200 nanometers. The ‘necked’ narrower regions may reach dimension as small 





















Figure 14: Micrograph of Layered Depostion 
4.5 Crystallinity Evaluation 
To evaluate the amorphicity of the deposited indomethacin, X-Ray Diffraction will 
be used. Deposited particles only reach thicknesses <10 𝜇𝑚 during reasonable 
experimental time scales, so Thin Film X-Ray Diffraction is utilized for evaluation.  
4.5.1 Literature 
Hernandez et. al. performed X-Ray Diffraction on two different polymorphs of 
Indomethacin as well as the amorphous state. A Siemens Kristalloflex 5000 diffractometer 
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was used. Their data are presented in Figure 15. Curve C represents the diffraction 
pattern of the 𝛾 crystal, curve B shows the 𝛼 crystal, and curve A is amorphous. 
 
Figure 15: X Ray Diffraction of Indomethacin in Various Forms from Literature 
4.5.2 Experimental 
For crystallinity evaluation of electrospray deposited particles, X-ray diffraction 
was performed on a Rigaku D/MAX XRD with a 40kV Copper X-ray tube, 2 Theta 
Goiniometer, Datascan 4 Acquisition Software, and a thin film diffraction attachment. 
Both a crystalline sample and amorphous sample were analyzed. Figure 16 shows both 
curves gathered on the same axes. 2𝜃 spanned 10-40 degrees. The incident angle was held 
constant at 5 degrees. Because IMC is an organic molecule, diffraction is expected only at 
lower angles; this is supported by literature (Hernadez et al). 
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The diffracted sample used the standard solution of this study (1.5%wt, .15 mL/h) 
with a sample exposure time of 60 minutes. This elongated exposure time allows the 
sample to obtain a sufficiently thick coating for analysis. At this time, the thickness of the 
film is underestimated to be on the order of the diameter of the particles. This guarantees 
at least a monolayer thickness, particularly at the core of the spray. Figure 16 shows the 
diffraction data of the amorphous sample (quite flat and blue) superposed over the 
diffraction data for the crystalline powder (substantially higher peaks and red). 
 
Figure 16: Experimental X-ray Diffraction of Amorphous and Crystalline IMC 
The data demonstrates strong agreement with literature. We conclude that spray dried 
IMC lacks crystalline structure, as predicted. 
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4.5.3 Extra Evidence of Amorphicity 
As discussed above, the amorphous state is a thermodynamically unstable solid 
form. It exhibits great molecular mobility and given time will change quite drastically, 
especially if stored under stressful conditions. The changes which occur center strongly 
around reverting to a crystalline form. In an attempt to understand this reversion to a 
crystalline form, a sample of sprayed indomethacin was aged for 5 weeks in a nitrogen 
environment. The sample was stored at room temperature which stresses the solid by 
being within 50℃ of its glass transition temperature (Newman 2010). The experimental 
parameters of the deposition are presented in table 7. 
Table 7: Aging Study Experimental Parameters 
 
The resulting micrographs of this study are quite striking with respect to the 























example of how crystals propagate through an amorphous sample. It also starkly 
demonstrates the difference in appearance between the sprayed sample (top middle) 
and crystalline indomethacin (the rest).  
 
Figure 17: Crystal propagation over aged sample 
 Figure 18 shows a detail of the boundary between crystal and amorphous 




Figure 18: Crystal Propagation detail 
 The most striking aspect of this micrograph is how amazingly sharp the boundary 
appears between crystal and amorphous sample. We conclude this is due to a 
propagation of crystal like a wave through the sample. Initially, crystalline seeds nucleate 
spontaneously from the amorphous solid and then grow at the boundaries of the 





Figure 19: Crystalline seed nucleated from amorphous solid 
 Because the sample seems to have deteriorated over time to a crystal form, the 
sample must have started without crystal structure. These aging studies support the 
diffraction data. 
4.6 Solubility Advantage Verification 
Solubility data are obtained with UV-Vis spectrophotometry in coordination with 
Beer’s Law. Explorations seek to evaluate the dissolution profile of sprayed indomethacin 
against crystalline indomethacin. This dissolution profile is then compared to the 
dissolution profile obtained by Hancock and Parks. 
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4.6.1 Beers Law 
Beer’s law expresses the relationship between concentration in solution and 
absorbance. The explicit statement of Beer’s law is stated as 
𝐴 = 𝜖𝑏𝑐.      (10) 




,      (11) 
to the molar absorptivity, optical path length, and concentration of solute. 
This simple relationship allows the calculation of concentration of a substance in 
solution given a fixed path length and known molar absorptivity. Because molar 
absorptivity depends functionally on wavelength, Beer’s law is most appropriately 
applied at a specific wavelength. 
4.6.2 UV Vis Spectrophotometry 
A spectrophotometer measures the amount of light a sample absorbs. The device 
releases a luminous pulse of known intensity through a sample solution and measures 
the intensity of the light after it leaves the sample. Recalling the definition of absorbance, 
a decreasing measured intensity clearly accompanies an increasing absorbance.  
UV-Vis Spectrophotometry describes a spectrophotometer which operates 
between the ultraviolet and visual spectra. This type of spectrophotometer is necessary 
for the analysis of IMC since the ‘spectral peaks’ of indomethacin occur at 230, 260, and 




UV-Vis spectrophotometry, coupled with Beer’s law and cuvettes of known 
optical path length, allows the evaluation of the dissolution profile of spray deposited 
indomethacin and a crystalline standard. In order to test the dissolution profile, an excess 
of amorphous sample dissolves into deionized water. Samples are taken periodically as 
the dissolution proceeds and subjected to spectrophotometry. 
 In this study, the excess of amorphous sample was determined to be two hours of 
deposition (roughly three milligrams) in a 50 mL volume of deionized water. Since the 
saturation solubility of crystalline indomethacin is roughly 1 mg/L, this volume 
represents a potential 30 fold supersaturation. Since this value could never actualize, it 
represents an ‘excess’. Samples (after the blank sample) were taken every 6 minutes with 
the first sample being taken 3 minutes after the addition of solute. Similarly, the control 
study used 3 mg of crystalline IMC (Sigma Aldrich) in 50 mL of de ionized water with 
samples being taken identically to the amorphous group.  
The sample group and control constituted 50 spectral analyses total. The strongest 
response came from the spectral peak at 260 nm. The value of absorbance at 260 nm was 
isolated from each spectrum and compiled in a table, paired with its corresponding time. 
The constant of proportionality (necessitated by Beer’s law) was evaluated via the known 
value of saturation for crystalline indomethacin (.937 mg/L) along with the averaged 
value of the control sample absorbance. This gave a constant of proportionality as .474 
L/mg. After transforming the absorbance data into concentration data, the two data sets 
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(amorphous and control) were superposed over their identical time scales. The results are 
presented in Figure 20. 
 
Figure 20: Dissolution Study Results 
These results are consistent with data taken from the 318 nm spectral peak, but 
this profile is omitted due to redundancy. We predict the stark variation and apparent 
instability in crystalline data derives from sample present concentration gradients and 
perhaps insufficient mixing. It would seem that the amorphous sample avoided the same 
problems but the nature of this unpredictable variation in the control is beyond the scope 
of this investigation. Clearly, the steady state concentration of the amorphous 
nanoparticles far exceeds that of the crystalline control. In fact, the steady value delivers 


























Dissolution Profile of Amorphous and 
Crystalline Indomethacin in DI Water 




that the profile of sprayed IMC, though conducted at room temperature, bears a much 
closer resemblance to the Hancock and Parks amorphous indomethacin dissolution test 
conducted at 5℃ than the test conducted at 25℃. We do not speculate towards reasons 
or mechanisms for this but observe that the spring is less violent and the parachute 




CHAPTER 5: CONCLUSIONS  
 
We conclude that electrospray represents an high potential emerging method for 
the production of amorphous nanoparticles. Electrospray succeeded in producing 
particles of submicron diameter and aspherical morphology with high monodispersity. 
These particles evaporated quickly enough to exhibit high amorphicity as well as a 
substantial aqueous solubility advantage.  Coupled with the potential for scale up to 
industrial throughputs, electrospray presents a strong case for feasible powder 
production of active pharmaceutical ingredients. Though the particles in this study were 
deposited on a silicon substrate, the ultimate goal is a powder for pharmaceuticals. This, 
however, is work which has already been accomplished for other spray drying 
techniques with cyclone technology.  
 Other work in post processing involves the solid solution of drug particles 
with various polymer excipients. The same principles presented in this study apply 
equally to those efforts. The primary challenge in those explorations is the complexity of 
the solution. Each case is unique and requires special care. After the solution properties 
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